Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043875 · ClinicalTrials.gov registry record · Phase 2
Pediatric Epilepsy Trial in Subjects 1-24 Months
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT00043875 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 177 participants.
The verdict
NCT00043875, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.
Interventions
- DRUG lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2000-05 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043875
The ClinicalTrials.gov registry entry for NCT00043875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lamotrigine is the first listed.
NCT00043875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00043875 about?
NCT00043875 is a clinical study titled "Pediatric Epilepsy Trial in Subjects 1-24 Months". This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 y...
What is the current status of trial NCT00043875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2000-05. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00043875?
The interventions under investigation include: lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00043875?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.